Wolfgang E. Schmidt

TL;DR: Liraglutide once a day provided significantly greater improvements in glycaemic control than did exenatide twice a day, and was generally better tolerated, suggesting that liragLutide might be a treatment option for type 2 diabetes, especially when weight loss and risk of hypoglycaemia are major considerations.

TL;DR: Deteriorations in glucose homeostasis can develop in the absence of any impairment in GIP or GLP-1 levels, which suggests that the defects in GLP1 concentrations previously described in patients with long-standing type 2 diabetes are likely secondary to other hormonal and metabolic alterations, such as hyperglucagonemia.

TL;DR: Glucagon secretion is dose-dependently stimulated by GIP at basal glucose concentrations, and this results underline differences between GIP and the glucagonostatic incretin GLP-1.

TL;DR: GLP-1 improves postprandial lipidaemia, presumably as a result of delayed gastric emptying and insulin-mediated inhibition of lipolysis, and may reduce the cardiovascular risk in patients with type 2 diabetes.

TL;DR: GLP-2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying, and changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during GLp-2 administration.